Trial Profile
Phase I study of cetuximab plus U3-1565 in colorectal cancer with resistance to anti-EGFR antibody
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Feb 2020
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; U3 1565 (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- 24 Apr 2019 Status changed to completed as per results published in the Investigational New Drugs
- 24 Apr 2019 Results published in the Investigational New Drugs
- 03 Aug 2014 Status changed from planning to recruiting as reported by University Hospital Medical Information Network - Japan